Stereotactic Irradiation of GH-Secreting Pituitary Adenomas

Table 1

Summary of results of recent series on SRS for GH-secreting pituitary adenomas.

Authors	patients No	Type of SRS	Total dose Gy	followup median (months)	Tumor control (%)	Hormone normalization (%)	Late toxicity (%)
							Visual	Hypopituitarism
Morange-Ramos et al. [23]	15	GK SRS	28	20	NA	20	5	16
Lim et al. [24]	20	GK SRS	25	26	92.5	30	5	5
Landolt et al. [25]	16	GK SRS	25	17	NA	50	0	0
Kim et al. [26]	11	GK SRS	28.7	27	NA	35	0	0
Inoue et al. [27]	12	GK SRS	21	>24	94	58	NA	NA
Mokry et al. [28]	10	GK SRS	16	46	100	31	0	NA
Izawa et al. [29]	29	GK SRS	22.5	>6	100	41	0	0
Zhang et al. [30]	68	GK SRS	31	32	NA	40	1.3	4
Landolt et al. [31]	31	GK SRS	25	19.2	NA	69	NA	NA
Ikeda et al. [32]	17	GK SRS	25	58	NA	82	0	0
Pollock et al. [33]	26	GK SRS	20	36	100	47	0	16
Swords et al. [34]	13	LINAC SRS	8–15	25	100	35	0	0
Choi et al. [35]	12	GK SRS	28.5	43	100	30	0	0
Attanasio et al. [36]	30	GK SRS	20	46	100	30 at 5 years	0	6.7
Jane et al. [37]	64	GK SRS	15	>18	NA	36	0	28
Castinetti et al. [38]	82	GK SRS	26	49.5*	NA	17	1.2	17
Gutt et al. [39]	44	GK SRS	23	22	100	48	NA	NA
Kobayashi et al. [40]	67	GK SRS	18,9	63	100	17	11	15
Jezková et al. [41]	96	GK SRS	32	53.7	100	44 at 5 years	0	27.1
Voges et al. [42]	64	LINAC SRS	16,5	54.3	97	14 and 33 at 3 and 5 years	1.4	13 and 18 at 3 and 5 years
Petit et al. [43]	22	Proton SRS	20 CGE	75.6	100	59	0	38
Pollock et al. [44]	46	GK SRS	20	63	100	11 and 60 at 2 and 5 years	0	33 at 5 years
Vik-Mo et al. [45]	53	GK SRS	26.5	67	100	58 and 86 at 5 and 10 years	3.8	10 at 5 years
Jagannathan et al. [46]	95	GK SRS	22	57	98	36 and 47 at 3 and 5 years	4	34
Losa et al. [47]	83	GK SRS	21,5	69	97	52 and 85 at 5 and 10 years	0	10 at 10 years
Ronchi et al. [48]	35	GK SRS	20	114	100	15 and 46 at 5 and 10 years	0	69
Wan et al. [49]	103	GK SRS	21,4	67	95	37	0	6
Hayashi et al. [50]	25	GK SRS	25.2	36	100	40	0	0
Iwai et al. [51]	26	GK SRS	20	84	96	17 and 47 at 5 and 10 years	0	8
Milker-Zabel et al. [55]	20	FSRT	52.2	61	100	80 at 5 years	5	15
Colin et al. [56]	31**	FSRT	50.4	80	99	20 and 50 at 5 and 10 years	0	37
Minniti et al.[57]	18**	FSRT	45	39	98	50 at 5 years*	0	22
Imran et al. [58]	12	FSRT	50	28.5	92	33	0	8
Roug et al. [59]	34	FSRT	54	45	91	36 at 5 years	NA	29

NA not assessed.
*mean followup; **acromegalic patients included in series of FSRT for either secreting or non secreting pituitary tumors.